Recent Updates
Recently added Catalysts
ACHC Positive Sentiment

Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Healthcare Company, Inc. has announced the date for its second quarter 2026 earnings release, which will occur on July 28, 2026. Following the release, a conference call with institutional investors and analysts is scheduled for July 29, 2026, at 9:00 a.m. ET. The call will be accessible via a live broadcast on their website.
Price reaction · baseline $31.4 (2026-07-09 close) · hit after-hours · clean, no other ACHC news in the window
day 0 close
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Healthcare is proactively communicating its earnings release date.
  • The scheduled conference call indicates transparency with investors.
  • The company is engaging with institutional investors and analysts.

Full Press Release Details

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be availabl

Frequently Asked Questions

When will Acadia Healthcare release its Q2 2026 results?

Acadia Healthcare will release its Q2 2026 results on July 28, 2026.

What time is the conference call for Q2 2026 results?

The conference call is scheduled for July 29, 2026, at 9:00 a.m. ET.

Where can I listen to the earnings call?

The earnings call will be available live on Acadia's website in the 'Investors' section.

ShareAdd on Google
Tags: ACHC Viatris Investor Conferences Healthcare Acadia Healthcare earnings release Q2 2026 conference call
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$171M liquidity · $0M/mo burn
Low dilution risk